Balaxi Pharmaceuticals Ltd
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
- Market Cap ₹ 138 Cr.
- Current Price ₹ 25.0
- High / Low ₹ 63.9 / 15.2
- Stock P/E 97.2
- Book Value ₹ 45.1
- Dividend Yield 0.00 %
- ROCE 3.11 %
- ROE 0.59 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.55 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.15% over past five years.
- Company has a low return on equity of -3.58% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 184 days.
- Promoter holding has decreased over last 3 years: -6.70%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 14 | 46 | 231 | 279 | 336 | 241 | 293 | 270 | |
| 12 | 37 | 189 | 229 | 279 | 197 | 260 | 262 | |
| Operating Profit | 2 | 8 | 43 | 51 | 57 | 45 | 32 | 9 |
| OPM % | 11% | 18% | 18% | 18% | 17% | 18% | 11% | 3% |
| 1 | 1 | 2 | 5 | 3 | -38 | 2 | 3 | |
| Interest | 0 | 0 | 0 | 1 | 1 | 3 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 9 | 44 | 55 | 57 | 2 | 29 | 5 |
| Tax % | 19% | 31% | 14% | 13% | 19% | 219% | 13% | 73% |
| 2 | 6 | 38 | 48 | 46 | -2 | 25 | 1 | |
| EPS in Rs | 1.30 | 1.22 | 7.63 | 9.53 | 9.03 | -0.44 | 4.54 | 0.26 |
| Dividend Payout % | 0% | 0% | 0% | 1% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -7% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -48% |
| 3 Years: | -69% |
| TTM: | -94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | -27% |
| 3 Years: | -39% |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | -4% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 10 | 10 | 10 | 10 | 11 | 11 | 11 |
| Reserves | 0 | 18 | 55 | 103 | 173 | 190 | 221 | 238 |
| 0 | 0 | 4 | 4 | 13 | 19 | 53 | 58 | |
| 3 | 8 | 31 | 60 | 43 | 38 | 25 | 30 | |
| Total Liabilities | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 |
| 0 | 0 | 2 | 29 | 41 | 41 | 41 | 82 | |
| CWIP | 0 | 0 | 0 | 1 | 3 | 2 | 22 | 0 |
| Investments | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| 6 | 36 | 94 | 147 | 195 | 215 | 247 | 255 | |
| Total Assets | 6 | 36 | 100 | 176 | 240 | 258 | 310 | 337 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| -2 | -14 | 0 | 34 | 6 | 5 | -35 | -4 | |
| -0 | -0 | -6 | -28 | -11 | -1 | -22 | -21 | |
| 0 | 18 | 4 | -0 | 26 | 30 | 34 | 0 | |
| Net Cash Flow | -2 | 4 | -2 | 6 | 21 | 34 | -23 | -25 |
| Free Cash Flow | -2 | -14 | -3 | 7 | -9 | 4 | -57 | -25 |
| CFO/OP | -97% | -161% | 6% | 78% | 32% | 26% | -98% | 3% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 147 | 238 | 121 | 36 | 57 | 84 | 138 | 184 |
| Inventory Days | 9 | 29 | 184 | 189 | 233 | 173 | 202 | |
| Days Payable | 64 | 53 | 92 | 62 | 82 | 36 | 51 | |
| Cash Conversion Cycle | 147 | 183 | 97 | 129 | 184 | 235 | 275 | 335 |
| Working Capital Days | 82 | 181 | 91 | 92 | 122 | 142 | 186 | 236 |
| ROCE % | 57% | 93% | 60% | 37% | 21% | 13% | 3% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Product Registrations (Cumulative) Number |
|
|||||
| Warehouse Network Number |
||||||
| Geographic Presence (Countries) Number |
||||||
| Product Registration Pipeline Number |
||||||
| Working Capital Cycle (GCA Days) Days |
||||||
Extracted by Screener AI
Documents
Announcements
-
Copy of Newspaper Publication
30 May 2026 - Published audited standalone and consolidated results for quarter and year ended 31 March 2026.
-
Investor Presentation
29 May 2026 - Investor presentation on Q4/FY26 results; Hyderabad formulation plant commissioning complete.
-
Outcome of Board Meeting
28 May 2026 - FY26 audited results approved; Jadcherla plant got manufacturing licence on 23 May 2026, commercialization ready.
-
Outcome of Board Meeting
28 May 2026 - Board approved FY26 results; Jadcherla plant got manufacturing licence on 23 May, ready for commercialization.
-
Appointment
28 May 2026 - Board approved FY26 audited results; Jadcherla plant received manufacturing licence and is ready for commercialization.
Annual reports
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
Aug 2022TranscriptAI SummaryPPT
-
Jun 2022TranscriptAI SummaryPPT
-
Jun 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Jul 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Oct 2020TranscriptAI SummaryPPT
Product Portfolio
The company is a branded IPR-based pharmaceutical player focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs across multiple therapeutic segments. As of 9M FY25, it has a portfolio of 897 registered products across 7 countries in Africa and Latin America serving through 38 warehouses. [1] [2] [3]